Tim Labranche

Tim LaBranche has extensive work experience in the field of preclinical safety and toxicology, primarily in the pharmaceutical industry. Tim started their career at Pfizer in 2006, where they served as a Principal Scientist in the Toxicology and Veterinary Pathology department. In this role, they were responsible for supporting non-oncology discovery programs and collaborating on the development of novel animal models for rheumatoid arthritis.

In 2008, LaBranche was promoted to Senior Principal Scientist at Pfizer, where they continued their work in toxicology and veterinary pathology. Tim took on additional responsibilities as a Drug Safety Team Representative and Principal Investigator for projects related to the rheumatology therapeutic area. Notably, they led a multi-disciplinary team in the study of the mechanism of action of the JAK inhibitor tofacitinib in a bone destruction animal model, which resulted in publications in prominent scientific journals.

LaBranche joined Blueprint Medicines in 2015 as the Senior Director of Preclinical Safety. During their tenure, they played a crucial role in ensuring the safety of preclinical drug candidates. In February 2021, they were promoted to the position of Vice President, further demonstrating their expertise and leadership in the field.

Throughout their career, LaBranche has demonstrated a strong commitment to drug safety and has collaborated with various teams to advance scientific understanding in their field.

Tim LaBranche holds a Doctor of Veterinary Medicine degree from the Virginia-Maryland College of Veterinary Medicine, which they obtained from 1999 to 2003. Tim also earned their PhD in Pharmacology & Toxicology from the same institution, completing it from 1996 to 2004. Following this, they pursued an Anatomic Pathology Residency at The University of Georgia from 2004 to 2006. Tim LaBranche's undergraduate studies were in Animal Science, where they received a Bachelor of Science degree from Virginia Tech between 1992 and 1996. Additionally, they obtained a Board Certification, American College of Veterinary Pathologists in 2007 and underwent Strategy Execution certification from Harvard Business School Online, anticipated to be completed in 2023.